31 Jul 2017 13:45
RNS Number : 6090M
SalvaRx Group plc
31 July 2017
SalvaRx Group plc
("SalvaRx" or "the Company")
Result of AGM
SalvaRx (LON: SALV), the drug discovery and development company focused on cancer immunotherapy, is pleased to announce that at its Annual General Meeting, which was held earlier today, all resolutions were duly passed.
For more information on SalvaRx please visit: www.salvarx.io
SalvaRx Group plc | |
Ian Walters (Chief Executive) | Tel: +1 203 441 5451 |
Northland Capital Partners Limited Nominated Adviser and Broker | Tel: +44 (0) 20 3861 6625
|
Matthew Johnson / Edward Hutton (Corporate Finance) | |
John Howes (Corporate Broking) |
Peterhouse Corporate Finance Limited Joint Broker Lucy Williams / Duncan Vasey | Tel: +44 (0) 20 7469 0932 |
This information is provided by RNS
The company news service from the London Stock Exchange